BiotechTube
Cellistic

Cellistic

Ghent, Belgium· Est.
cellistic.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cellistic is a specialized CDMO exclusively focused on iPSC-derived allogeneic cell therapy manufacturing. It offers a full spectrum of services, including proprietary platforms like Pulse for cell line development and Echo for scalable GMP manufacturing, all housed in a purpose-built, EMA-certified facility in Belgium. The company positions itself as a strategic partner to help biotechs accelerate development, reduce costs, and overcome the scalability limitations of autologous or donor-derived approaches. Its integrated model combines deep iPSC expertise with pre-established platforms to de-risk and streamline client programs.

OncologyRegenerative Medicine

Technology Platform

Proprietary platforms for iPSC-based cell therapy manufacturing: Pulse™ (for iPSC cell line development with STAR-CRISPR™ gene-editing) and the Echo™ Manufacturing Platform (for scalable GMP differentiation into specific cell types like NK, T, cardio, and endothelial cells).

Opportunities

The company is positioned at the convergence of two high-growth trends: the expansion of the cell therapy market and the industry-wide shift from autologous to scalable allogeneic iPSC-based therapies.
As a specialized CDMO, it addresses a critical bottleneck in manufacturing, offering a service model with recurring revenue potential from long-term client contracts.

Risk Factors

Key risks include intense competition from larger, diversified CDMOs and niche players, execution risk in operating a complex GMP facility, and technology adoption risk if the iPSC allogeneic therapy field develops slower than expected.
As a young, capital-intensive private company, it also faces financing and client-concentration risks.

Competitive Landscape

Cellistic competes in the cell therapy CDMO space against large, established players like Lonza, Catalent, and Charles River Laboratories, which have broader but less iPSC-specialized capabilities. It also faces competition from other focused CDMOs and biotechs with internal manufacturing expertise. Its differentiation is its exclusive focus on iPSCs and its integrated platform approach.

More companies in Cell & Gene Therapy →More companies in Belgium →